Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

COPD: new developments and therapeutic opportunities.

P Norman1

  • 1Norman Consulting, Burnham, Buckinghamshire, UK.

Drug News & Perspectives
|December 24, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Working with Insulin, Carbohydrates, Ketones and Exercise to Manage Diabetes (WICKED): evaluation of a self-management course for young people with Type 1 diabetes.

Diabetic medicine : a journal of the British Diabetic Association·2019
Same author

Experiences of self-management among young adults with Type 1 diabetes in the context of a structured education programme: a qualitative study.

Diabetic medicine : a journal of the British Diabetic Association·2018
Same author

Optical absorption and magnetic circular dichroism spectra of thiouracils: a quantum mechanical study in solution.

Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology·2017
Same author

Geographic variation in the treatment of non-ST-segment myocardial infarction in the English National Health Service: a cohort study.

BMJ open·2016
Same author

The importance of mindfulness in psychosocial distress and quality of life in dermatology patients.

The British journal of dermatology·2016
Same author

Patient and hospital determinants of primary percutaneous coronary intervention in England, 2003-2013.

Heart (British Cardiac Society)·2016
Same journal

New drug discovery and development in India.

Drug news & perspectives·2013
Same journal

Are we living in the end of the blockbuster drug era?

Drug news & perspectives·2010
Same journal

Molecule of the Month. TAK-875.

Drug news & perspectives·2010
Same journal

Epigenetic alterations of tumor marker microRNAs: towards new cancer therapies.

Drug news & perspectives·2010
Same journal

Electroporation: a promising method for the nonviral delivery of DNA vaccines in humans?

Drug news & perspectives·2010
Same journal

Trioxaquines: hybrid molecules for the treatment of malaria.

Drug news & perspectives·2010
See all related articles

Current chronic obstructive pulmonary disease (COPD) treatments have limitations. Novel therapies, including retinoic acid for alveolar growth and M(3)-selective muscarinic antagonists, show promise for future COPD management.

Area of Science:

  • Pulmonary Medicine
  • Pharmacology

Background:

  • Chronic obstructive pulmonary disease (COPD) presents therapeutic challenges.
  • Current treatments for COPD, such as bronchodilators, have varying efficacy and application.
  • The role of steroids and antibiotics in COPD management remains unclear.

Purpose of the Study:

  • To review current therapeutic deficiencies in COPD.
  • To explore potential benefits of novel approaches for COPD treatment.
  • To discuss advancements in understanding COPD pathophysiology and treatment.

Main Methods:

  • Symposium review of existing COPD therapies and novel approaches.
  • Discussion of computerized tomographic (CT) scanning utility.
  • Presentation of preclinical findings on retinoic acid's effect on alveolar growth in hamsters.

Related Experiment Videos

Main Results:

  • Computerized tomographic (CT) scanning offers both quantitative and qualitative assessment in COPD.
  • Retinoic acid demonstrated potential for inducing new alveolar growth in an animal model.
  • Bronchodilators are primary current therapies; mucolytic use is inconsistent.
  • Evidence for clinical benefit of antibiotics in COPD is limited; steroid role is debated.

Conclusions:

  • Significant limitations exist in current COPD therapies.
  • Novel therapeutic strategies, including M(3)-selective muscarinic antagonists, chemotactic mediators, protease inhibitors, and anti-inflammatory agents, warrant further investigation.
  • Retinoic acid presents a potential avenue for regenerative therapy in COPD.